Glaxo agrees to pay $3B, and its stock price goes up.
The agreement is expected to be completed next year, and the settlement will be paid through the company's cash resources, GSK said.
The company said the proposed settlement covered its sales and marketing practices for drugs including antidepressants Paxil and Wellbutrin, an investigation begun by the U.S. Attorney's office of Colorado in 2004 and later taken over by the U.S. Attorney's Office of Massachusetts; the U.S. Justice Department's investigation of possible inappropriate use of the nominal price exception under the Medicaid Rebate Program; and the Justice Department's investigation of the development and marketing of the diabetes drug Avandia."
'via Blog this'
No comments:
Post a Comment